Seeking Alpha
28 Jul 2026, 21:29 UTC · 3h ago
Compass Pathways: The Psilocybin Biotech Leader With Strong Momentum
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
28 Jul 2026, 21:29 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Compass Pathways has completed two successful Phase 3 trials and is currently executing a rolling FDA submission for COMP360. — Successful late-stage trials and active FDA submission are the primary catalysts for commercialization and revenue generation.
+0.80Eli Lilly's acquisition of Atai validates the psilocybin sector and increases the competitive landscape. — Big Pharma entry provides sector-wide validation and potential M&A tailwinds, though it introduces stronger competition.
+0.40COMP360 has demonstrated encouraging data for PTSD and other potential indications beyond treatment-resistant depression. — Expansion into additional indications increases the long-term total addressable market (TAM).
+0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
The company has two successful Phase 3 trials and a head start in treatment-resistant depression.
Entering the field through Atai validates the sector, though it increases competition.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Business Wire
46m ago
